Top

23-11-2015 | Genitourinary cancers | Article

Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study

Journal: Supportive Care in Cancer

Authors: Frances J. Drummond, Eamonn O’Leary, Anna Gavin, Heather Kinnear, Linda Sharp

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

Many men with prostate cancer are asymptomatic, diagnosed following prostate specific antigen (PSA) testing. We investigate whether mode of detection, i.e. ‘PSA detected’ or ‘clinically detected’, was associated with psychological wellbeing among prostate cancer survivors.

Methods

A cross-sectional postal questionnaire was administered in 2012 to 6559 prostate cancer (ICD10 C61) survivors up to 18 years post-diagnosis, identified through population-based cancer registries in Ireland. Psychological wellbeing was assessed using the Depression Anxiety Stress Scale-21. Logistic regression was used to investigate associations between mode of detection and depression, anxiety and stress, adjusting for socio-demographic and clinical confounders.

Results

The response rate was 54 % (3348/6262). Fifty-nine percent of survivors were diagnosed with asymptomatic PSA-tested disease. Prevalence of depression (13.8 vs 20.7 %; p < 0.001), anxiety (13.6 vs 20.9 %; p < 0.001) and stress (8.7 vs 13.8 %; p < 0.001) were significantly lower among survivors diagnosed with PSA-detected, than clinically detected disease. After adjusting for clinical and socio-demographic factors, survivors with clinically detected disease had significantly higher risk of depression (odds ratio (OR) = 1.46 95 % CI 1.18, 1.80; p = 0.001), anxiety (OR = 1.36 95 % CI 1.09, 1.68; p = 0.006) and stress (OR = 1.43 95 % CI 1.11, 1.85; p = 0.006) than survivors with PSA-detected disease.

Conclusions

These findings contribute to the ongoing debate on benefits and risks of PSA testing and may be considered by policy makers formulating population-based prostate cancer screening policies. The relatively high prevalence of negative psychological states among survivors means that a ‘risk-adapted approach’ should be implemented to screen survivors most at risk of psychological morbidity for psychological health, and mode of detection could be considered as a risk stratum.

Raffle AE, Gray JAM (2007) Screening: evidence and practice. Oxford University Press

McCarthy M (2014) Canadian panel recommends against PSA screening. BMJ. doi:10.1136/bmj.g6556

Rychetnik L, Doust J, Thomas R, Gardiner R, Mackenzie G, Glasziou P (2014) A community jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening–a qualitative analysis. BMJ Open. doi:10.1136/bmjopen-2013-004682

Drummond FJ, Carsin AE, Sharp L, Comber H (2010) Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Ir J Med Sci. doi:10.1007/s11845-009-0376-7 PubMed

Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96:1358–1367CrossRefPubMed

Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A (2010) Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control. doi:10.1007/s10552-010-9581-y PubMed

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators ERSPC (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. doi:10.1016/S0140-6736(14)60525-0

Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Project Team PLCO (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. doi:10.1093/jnci/djr500

Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004720.pub3

10.

Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG (2007) Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 69:215–220CrossRefPubMedPubMedCentral

11.

Scott JG, Shaw EK, Friedman A (2013) Emotional consequences of persistently elevated PSA with negative prostate biopsies. Am J Can Prev 1:4–8CrossRef

12.

Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. doi:10.1016/S1470-2045(13)70244-4

13.

Yang YL, Liu L, Wang Y, Wu H, Yang XS, Wang JN, Wang L (2013) The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis. BMC Cancer. doi:10.1186/1471-2407-13-393

14.

National Prostate Cancer General Practitioner Referral Guidelines. National Cancer Control Programme. http://www.healthlink.ie/Oncology/NCCP%20Prostate%20Cancer%20Referral%20Guideline%20Version%201.3%20January%202011.pdf. Accessed 8th December 2011

15.

Prostate Cancer: diagnosis and treatment. National Institute for Health and Care Excellence (NICE). http://www.nice.org.uk/guidance/cg175/chapter/1-recommendations, Accessed 9th July 2014

16.

Drummond FJ, Kinnear H, Donnelly C, O’Leary E, O’Brien K, Burns RM, Gavin A, Sharp L (2015) Establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions: the Prostate Cancer Treatment, your experience (PiCTure) study. BMJ Open. doi:10.1136/bmjopen-2014-006851

17.

WMA Declaration of Helsinki—ethical principles for medical research involving human subjects (2008). http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed 9 July 2014.

18.

Lovibond SH, Lovibond PF (1995) Manual for the Depression Anxiety Stress Scales 2nd. Ed. Psychology Foundation, Sydney

19.

Crawford JR, Henry JD (2003) The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample. Br J Clin Psychol 42:111–131CrossRefPubMed

20.

Glaser AW, Fraser LK, Corner J, Feltbower R, Morris EJ, Hartwell G, Richards M, Wagland R (2013) Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. BMJ Open. doi:10.1136/bmjopen-2012-002317

21.

Norrish AR, McRae CU, Cohen RJ, Jackson RT (1999) A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int. doi:10.1046/j.1464-410x.1999.00168.x PubMed

22.

Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ (2012) Quality-of-life effects of prostate specific antigen screening. N Engl J Med. doi:10.1056/NEJMoa1201637 PubMedPubMedCentral

23.

Booth N, Rissanen P, Tammela TL, Määttänen L, Taari K, Auvinen A (2014) Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur Urol. doi:10.1016/j.eururo.2012.11.041 PubMed

24.

Walsh PM, McCarron P, Middleton RJ, Comber H, Gavin AT, Murray L (2006) Influence of mammographic screening on trends in breast-conserving surgery in Ireland. Eur J Cancer Prev 15:138–148CrossRefPubMed

25.

Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L (2005) Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. J Pain Symptom Manag 30:474–484CrossRef

26.

Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR (2013) A longitudinal study of anxiety, depression and stress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. doi:10.1111/bju.12209

27.

Sharpley CF, Christie DR, Bitsika V (2010) Variability in anxiety and depression over time following diagnosis in patients with prostate cancer. J Psychosoc Oncol. doi:10.1080/07347332.2010.516810 PubMed

28.

Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, Lewith G (2014) Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. doi:10.1136/bmjopen-2013-003901

29.

Bennett G, Badger TA (2005) Depression in men with prostate cancer. Oncol Nurs Forum 32:545–556CrossRefPubMed

30.

Sharpley CF, Bitsika V, Christie DR (2009) Understanding the causes of depression among prostate cancer patients: development of the Effects of Prostate Cancer on Lifestyle Questionnaire. Psychooncology. doi:10.1002/pon.1382 PubMed

31.

Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:348–354CrossRefPubMed

32.

Drummond FJ, Flahavan EM, Bennett K, Barron TI, Sharp L (2014) Prostate specific antigen testing is associated with men’s psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study. BMC Fam Pract. doi:10.1186/1471-2296-15-121 PubMedPubMedCentral

33.

Kotwal AA, Schumm P, Mohile SG, Dale W (2012) The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. doi:10.1097/MLR.0b013e318269e096 PubMedPubMedCentral

34.

Consedine NS, Adjei BA, Ramirez PM, McKiernan JM (2008) An object lesson: source determines the relations that trait anxiety, prostate cancer worry, and screening fear hold with prostate screening frequency. Cancer Epidemiol Biomark Prev. doi:10.1158/1055-9965.EPI-07-2538

35.

Dale W, Bilir P, Han M, Meltzer D (2005) The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 104:467–478CrossRefPubMedPubMedCentral

36.

Ransohoff DF, McNaughton Collins M, Fowler FJ (2002) Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113:663–667CrossRefPubMed

37.

Curtis R, Groarke A, Sullivan F (2014) Stress and self-efficacy predict psychological adjustment at diagnosis of prostate cancer. Sci Rep. doi:10.1038/srep05569 PubMedPubMedCentral

38.

Wootten AC, Burney S, Foroudi F, Frydenberg M, Coleman G, Ng KT (2007) Psychological adjustment of survivors of localised prostate cancer: investigating the role of dyadic adjustment, cognitive appraisal and coping style. Psycho-Oncology 16:994–1002CrossRefPubMed

39.

Folkman S, Greer S (2000) Promoting psychological well-being in the face of serious illness: when theory, research and practice inform each other. Psycho-Oncology 9:11–19CrossRefPubMed

40.

Ben-Tovim DI, Dougherty ML, Stapleton AM, Pinnock CB (2002) Coping with prostate cancer: a quantitative analysis using a new instrument, the centre for clinical excellence in urological research coping with cancer instrument. Urology 59:383–388CrossRefPubMed

41.

Couper JW, Love AW, Duchesne GM, Bloch S, Macvean M, Dunai JV, Scealy M, Costello A, Kissane DW (2010) Predictors of psychosocial stress 12 months after diagnosis with early and advanced prostate cancer. Med J Aust 193:S58–S61PubMed

42.

Hanly N, Mireskandari S, Juraskova I (2014) The struggle towards ’the new normal’: a qualitative insight into psychosexual adjustment to prostate cancer. BMC Urol. doi:10.1186/1471-2490-14-56 PubMedPubMedCentral

43.

Newby TA, Graff JN, Ganzini LK, McDonagh MS (2015) Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis. Psychooncology. doi:10.1002/pon.3781 PubMed

44.

Gallagher D, O’Regan C, Savva GM, Cronin H, Lawlor BA, Kenny RA (2012) Depression, anxiety and cardiovascular disease: which symptoms are associated with increased risk in community dwelling older adults? J Affect Disord. doi:10.1016/j.jad.2012.04.012

45.

Rauscher GH, Johnson TP, Cho YI, Walk JA (2008) Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomark Prev 17:748–757CrossRef

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.